Similarly, in CRC cells, genetic inhibition of either SREBP1 or SREBP2 leads to reduced tumor initiation and growth in vitro and in vivo, accompanied by decreased oxidative phosphorylation and glycolysis levels [25]. Here, SREBF1 is linked to neoplasm.